U.S. Markets close in 3 hrs 58 mins

Industry Analysts Just Upgraded Their Prothena Corporation plc (NASDAQ:PRTA) Revenue Forecasts By 92%

Simply Wall St

Shareholders in Prothena Corporation plc (NASDAQ:PRTA) may be thrilled to learn that the analysts have just delivered a major upgrade to their near-term forecasts. The consensus estimated revenue numbers rose, with their view now clearly much more bullish on the company's business prospects.

Following the upgrade, the current consensus from Prothena's eight analysts is for revenues of US$1.4m in 2020 which - if met - would reflect a major 80% increase on its sales over the past 12 months. Losses are expected to increase slightly, to US$2.14 per share. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$720k and losses of US$2.25 per share in 2020. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a sizeable increase to their revenue forecasts while also reducing the estimated loss as the business grows towards breakeven.

See our latest analysis for Prothena

NasdaqGS:PRTA Past and Future Earnings May 18th 2020

Of course, another way to look at these forecasts is to place them into context against the industry itself. One thing stands out from these estimates, which is that Prothena is forecast to grow faster in the future than it has in the past, with revenues expected to grow 80%. If achieved, this would be a much better result than the 14% annual decline over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in the industry are forecast to see their revenue grow 24% per year. Not only are Prothena's revenues expected to improve, it seems that the analysts are also expecting it to grow faster than the wider industry.

The Bottom Line

The most important thing here is that analysts reduced their loss per share estimates for this year, reflecting increased optimism around Prothena's prospects. Fortunately, analysts also upgraded their revenue estimates, and our data indicates sales are expected to perform better than the wider market. Given that analysts appear to be expecting substantial improvement in the sales pipeline, now could be the right time to take another look at Prothena.

Still, the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple Prothena analysts - going out to 2024, and you can see them free on our platform here.

Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are upgrading their estimates. So you may also wish to search this free list of stocks that insiders are buying.

Love or hate this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Thank you for reading.